RLMD (STOCKS)
Relmada Therapeutics, Inc. Common Stock
$7.380000
+0.090000 (+1.23%)
Prev close: $7.290000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Sergio Traversa
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $772.52M
- Employees
- 17
- P/E (TTM)
- -5.02
- P/B (TTM)
- 6.18
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.29 | $-0.14 | -0.1472 | -103.08% |
|
Sep 2025 (Q3)
|
$-0.30 | $-0.12 | -0.1817 | -153.59% |
|
Jun 2025 (Q2)
|
$-0.30 | $-0.26 | -0.0450 | -17.65% |
|
Mar 2025 (Q1)
|
$-0.58 | $-0.32 | -0.2638 | -83.43% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $1.72M |
| Operating Expenses | $59.10M |
| Research and Development | $26.88M |
| Other Operating Expenses | $32.22M |
| Operating Income/Loss | -$59.10M |
| Income/Loss From Continuing Operations After Tax | -$57.39M |
| Income/Loss From Continuing Operations Before Tax | -$57.39M |
| Net Income/Loss | -$57.39M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$57.39M |
| Net Income/Loss Available To Common Stockholders, Basic | -$57.39M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.45 |
| Diluted Earnings Per Share | -$1.45 |
| Basic Average Shares | 39,479,694 |
| Diluted Average Shares | 39,479,694 |
| Assets | $94.00M |
| Current Assets | $93.98M |
| Prepaid Expenses | $977.72K |
| Other Current Assets | $93.01M |
| Noncurrent Assets | $19.50K |
| Liabilities | $7.49M |
| Current Liabilities | $6.43M |
| Accounts Payable | $1.57M |
| Other Current Liabilities | $4.86M |
| Noncurrent Liabilities | $1.06M |
| Equity | $86.51M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $86.51M |
| Liabilities And Equity | $94.00M |
| Net Cash Flow From Operating Activities | -$45.79M |
| Net Cash Flow From Operating Activities, Continuing | -$45.79M |
| Net Cash Flow From Investing Activities | -$48.14M |
| Net Cash Flow From Investing Activities, Continuing | -$48.14M |
| Net Cash Flow From Financing Activities | $93.56M |
| Net Cash Flow From Financing Activities, Continuing | $93.56M |
| Net Cash Flow | -$360.49K |
| Net Cash Flow, Continuing | -$360.49K |
| Comprehensive Income/Loss | -$57.39M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$57.39M |
| Other Comprehensive Income/Loss | $0.00 |